THE TEAM

  • MR. JAY. W. HANDY
    MR. JAY. W. HANDY Acting CEO

    Jay is the Acting CEO of an investment management company. Prior to starting this company, Jay served as managing director of Merrill Lynch in Madison, WI. He has partaken in many national forums on diabetes, including HHS Secretary Tommy Thompson’s diabetes health initiatives. He is a graduate of Michigan State University and Harvard Business School. Jay has managed his own diabetes for 40 years.

  • MR. JEFF RUSINOW
    MR. JEFF RUSINOW Chairman

    Jeff Rusinow has been an active member of early-stage venture capital for over the past 15 years, and was the founder of Milwaukee’s first angel network. He has been chairman and lead investor in two startups that have been acquired by Fortune 500 companies. He spent 22 years in retail management, holding senior executive positions at Macy’s, Gimbel’s, Hudson Bay Company and Kohl’s Department Stores. Jeff has a B.A. and M.A. from the University of Virginia.

HANS SOLLINGER, M.D, PH.D, PRESIDENT & CO-FOUNDER

Dr. Hans Sollinger is considered the most experienced practicing pancreas-transplant surgeon in the world. He started his lab at the UW-Madison in 1993. For decades, he has been in communication with numerous top researchers and scientists searching for a cure for diabetes.

 

Funding Sources: Juvenile Diabetes Research Foundation, Roche Organ Transplantation Research Foundation, American Heart Association.

Societies and Boards: Past president of the American Society of Transplant Surgeons and the International Society of Organ Sharing; chairman on many industry boards and committees, including the American Society of Transplant Surgeons Ad Hoc Development Committee and the Advisory Committee on Organ Transplantation.

 

Other Professional Accomplishments: Author of nearly 500 manuscripts in peer reviewed journals, five books, and dozens of book chapters on organ transplantation.

 

Developed the most successful transplant drug in history , the immunosuppressant drug CellCept – $20 billion in revenue.

HOW IT WORKS

To achieve stable blood glucose control:

  1. We pack our patented gene construct into a vector (a benign virus)
  2. A clinician injects the vector into a vein
  3. The vector carries the gene to the liver and converts liver cells into effective, glucose responsive, insulin producing cells